Document is current
Any future updates will be listed below
-
Authors
Rohenkohl, Anja Christine http://orcid.org/0000-0001-7646-6358
Daubmann, Anne
Gallinat, Jürgen
Karow, Anne
Kraft, Vivien
Rühl, Friederike
Schöttle, Daniel
Lambert, Martin
Schröter, Romy
-
Funding
Funding for this research was provided by:
Universitätsklinikum Hamburg-Eppendorf (UKE)
- License Information
-
More Information
Article History
Received: 11 May 2022
Accepted: 17 August 2022
First Online: 8 September 2022
Declarations
:
: The local ethic committee (Ärztekammer Hamburg) approved the study as quality assurance study (registration number: PV4059). The study was registered at ClinicalTrials.gov (identifier: NCT01888627).Informed consent was obtained from all individual participants included in the study.
: The manuscript does not contain any individual person’s data in any form.
: Anja Christine Rohenkohl: has received speakers fee from Pfizer Pharma GmbH. Anne Daubmann: Nothing to declare. Jürgen Gallinat: Speaker fees from Lundbeck GmbH, Otsuka Pharma GmbH, Janssen Cilag GmbH, Boeringer Ingel-heim. Anne Karow: Consultant or speaker fees from AstraZeneca, Bristol-Myers Squibb, Lilly Deutschland GmbH, Janssen Cilag GmbH, Lundbeck GmbH, Otsuka Pharma GmbH, Roche Deutschland Holding GmbH. Vivien Kraft: Nothing to declare. Friederike Rühl: Nothing to declare. Daniel Schöttle: Consultant and/or advisor fees from Astra Zeneca, Otsuka Pharma GmbH, Lundbeck GmbH and Janssen Cilag GmbH. Martin Lambert: Consultant or speaker fees AstraZeneca, Bristol-Myers Squibb, Lilly Deutschland GmbH, Janssen Cilag GmbH, Lundbeck GmbH, Otsuka Pharma GmbH, Roche Deutschland Holding GmbH, Sanovi Aventis, Trommsdorff GmbH & Co. KG. Romy Schröter: Nothing to declare. The authors have no relevant financial or non-financial interests to disclose related to this manuscript.
